Nonalcoholic Steatohepatitis Treatment Market Booming in 2018 and Predicted to Achieve Double Digit CAGR by 2026

Nonalcoholic steatohepatitis has become one of the most common liver-related health problems. The condition has been linked to an unhealthy diet and weight gain, but it can also be observed in non-obese individuals. Increasing prevalence of insulin resistance, and obesity is expected to fuel the nonalcoholic steatohepatitis treatment market during the forecast period.

According to an article published in Lancet, globally, prevalence of overweight and obesity combined has risen by 27.5% for adults between 1980 and 2013. According to the National Health and Nutrition Examination Survey (NHANES) 2014 data, in U.S. the percentage of obesity is higher in women, i.e. 40%, than in men, 35%.

Get Exclusive Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/2279

Key players operating in the global nonalcoholic steatohepatitis treatment market include AstraZeneca Plc., Conatus Pharmaceuticals, Enzo Biochem, Inc., GENFIT SA, Galmed Pharmaceuticals Ltd., Gilead Science, Immuron Ltd., Intercepts Pharmaceuticals, Novo Nordisk, Raptor Pharmaceutical Corporation, and Tobira Therapeutics, Inc.

Moreover, no medicines have been approved to treat NASH so far. However, researchers are developing medicines to improve the conditions. According to the National Institute of Diabetes and Digestive and Kidney Diseases, some studies suggest that pioglitazone (Actos), a medicine for type 2 diabetes, can improve NASH in people non-diabetic patients.

Companies in the market are focusing on extensive research to develop medicine for NASH treatment. For instance, in 2017, Gilead Sciences, Inc. announced results from a Phase 2, randomized, placebo-controlled trial evaluating two doses of GS-0976, an oral, investigational inhibitor of Acetyl-CoA carboxylase, in patients with nonalcoholic steatohepatitis.

Nonalcoholic Steatohepatitis Treatment Market Restraints

Despite the significant burden to the public health system, there are no FDA-approved specifically tailored drugs for nonalcoholic steatohepatitis treatment. Therefore, there is an immense need for effective treatment to manage the complex pathophysiologic processes of NASH. Numerous medications targeting different stages and molecular events in the disease process are currently in the pipeline, increasing the promise of successful treatment of NASH in the future.

Nonalcoholic Steatohepatitis Treatment Market - Regional Insights

On the basis of region, the global nonalcoholic steatohepatitis treatment market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America and Europe nonalcoholic steatohepatitis treatment market is expected to foresee significant growth owing to increasing incidence of obesity and fatty liver.

According to the National Health and Nutrition Examination Survey, the proportion of NAFLD among chronic liver diseases increased from 47% to 75% between 1988 and 2008 in the U.S. According to the National Institutes of Health, in 2015 nearly 3 to 12% of adults in the U.S. were suffering from NASH. The major reason for this increase was an increase in metabolic risk factors. According to the Journal of Hepatology, in 2013, approximately one-third of adults exhibit a pattern of NAFLD in Europe.

Download PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/2279

Detailed Segmentation:

Global Nonalcoholic Steatohepatitis Treatment Market, By Drug:
Cenicriviroc
Elafibranor
Ocaliva (Obeticholic Acid)
Selonsertib
Global Nonalcoholic Steatohepatitis Treatment Market, By Distribution Channel:
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

Table of Contents

Research Objective and Assumption
Research Objectives
Assumptions
Abbreviations
Market Overview
Report Description
Market Definition and Scope
Executive Summary
Market Snippet, By Drug
Market Snippet, By Distribution Channel
Market Snippet, By Region
Coherent Opportunity Map (COM)
Market Dynamics, Regulations, and Trends Analysis
Market Dynamics
Drivers
Restraints
Market Opportunities
Impact Analysis
Market Trends
Key Developments
Research Studies
Pipeline Product Analysis
Epidemiology Study
PORTER’S Five Forces
Global Nonalcoholic Steatohepatitis Treatment Market, By Drug, 2016 – 2026, (US$ Million)
Introduction
Market Share Analysis, 2018 and 2026 (%)
Y-o-Y Growth Analysis, 2017 – 2026
Segment Trends
Cenicriviroc
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
Elafibranor
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
Ocaliva (Obeticholic acid)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
Selonsertib
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
Global Nonalcoholic Steatohepatitis Treatment Market, By Distribution Channel, 2016 – 2026, (US$ Million)
Introduction
Market Share Analysis, 2018 and 2026 (%)
Y-o-Y Growth Analysis, 2017 – 2026
Segment Trends
Hospital Pharmacy
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
Retail Pharmacy
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
Online Pharmacy
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
Global Nonalcoholic Steatohepatitis Treatment Market, By Region, 2016 – 2026, (US$ Million)
Introduction
Market Share Analysis, By Region, 2018 and 2026 (%)
Y-o-Y Growth Analysis, By Region, 2016 – 2026

Get Discount @ https://www.coherentmarketinsights.com/insight/request-discount/2279

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

1001 4th Ave,, #3200, Seattle, WA 98154

This release was published on openPR.